The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Evolving trends in mAb production processes
Open accessAbstract
Monoclonal antibodies (mAbs) have established themselves as the leading biopharmaceutical therapeutic modality. The establishment of robust manufacturing platforms are key for antibody drug discovery efforts to seamlessly translate into clinical and commercial successes. Several drivers are influencing the design of mAb manufacturing processes. The advent of biosimilars is driving a desire to achieve lower cost of goods and globalize biologics manufacturing. High titers are now routinely achieved for mAbs in mammalian cell culture. These drivers have resulted in significant evolution in process platform approaches. Additionally, several new trends in bioprocessing have arisen in keeping with these needs. These include the consideration of alternative expression systems, continuous biomanufacturing and non‐chromatographic separation formats. This paper discusses these drivers in the context of the kinds of changes they are driving in mAb production processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Viral clearance for biopharmaceutical downstream processes
Shukla, A. A., & Aranha, H. (2015) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.14.62 · Cited by 63
Self-citation
Cited by
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
Thakur, G., Hebbi, V., & Rathore, A. S. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27236 · Cited by 64
Welles, H. C., Jennewein, M. F., Mason, R. D., Narpala, S., Wang, L., Cheng, C., Zhang, Y., Todd, J.-P., Lifson, J. D., Balazs, A. B., et al. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007395 · Cited by 53
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics
Froning, K., Maguire, J., Sereno, A., Huang, F., Chang, S., Weichert, K., Frommelt, A. J., Dong, J., Wu, X., Austin, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16231-7 · Cited by 37
Real‐Time Nanoplasmonic Sensor for IgG Monitoring in Bioproduction
Tran, T., Eskilson, O., Mayer, F., Gustavsson, R., Selegård, R., Lundström, I., Mandenius, C.-F., Martinsson, E., & Aili, D. (2020) · Processes · doi:10.3390/pr8101302 · Cited by 24
Metadata
- Authors
- Shukla, A. A., Wolfe, L. S., Mostafa, S. S., & Norman, C.
- Venue
- Bioengineering & Translational Medicine
- Publisher
- Wiley
- Published
- 2017-03
- Volume
- 2
- Issue
- 1
- Pages
- 58-69
- ISSN
- 2380-6761 (ISSN-L)
- OpenAlex
- W2597907100
- Cited by
- 239
- References
- 2
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.